scispace - formally typeset
Y

Ying-Chao Duan

Researcher at Xinxiang Medical University

Publications -  21
Citations -  918

Ying-Chao Duan is an academic researcher from Xinxiang Medical University. The author has contributed to research in topics: Cancer & Epigenetics. The author has an hindex of 10, co-authored 18 publications receiving 737 citations. Previous affiliations of Ying-Chao Duan include Zhengzhou University.

Papers
More filters
Journal ArticleDOI

Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents.

TL;DR: Flow cytometry analysis demonstrated that treatment of MGC-803 with 3c led to cell cycle arrest at G2/M phase accompanied by an increase in apoptotic cell death after 12 h, and compound 3a was more potent than 5-fluorouracil against all tested human cancer cell lines.
Journal ArticleDOI

Triazole–Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration

TL;DR: Five series of 1,2,3-triazole-dithiocarbamate hybrids were designed and synthesized and screened their inhibitory activity toward LSD1 and it was found that some of these compounds exhibited the most specific and robust inhibition of LSD1.
Journal ArticleDOI

Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole–dithiocarbamate–urea hybrids

TL;DR: A series of novel 1,2,3-triazole-dithiocarbamate-urea hybrids were designed, synthesized and their antiproliferative activities against four selected human cancer cell lines were evaluated and showed that a number of the hybrids exhibited potent activity in selected humancancer cell lines.
Journal ArticleDOI

Targeting Brd4 for cancer therapy: inhibitors and degraders.

TL;DR: Recently, selective degradation of target proteins by small bifunctional molecules (PROTACs) has emerged as an attractive drug discovery approach owing to the advantages it could offer over traditional small-molecule inhibitors.
Journal ArticleDOI

Synthesis and biological evaluation of coumarin–1,2,3-triazole–dithiocarbamate hybrids as potent LSD1 inhibitors

TL;DR: Compound 8k showed potent and reversible inhibition against lysine specific demethylase 1 with an IC50 value of 0.39 μM, which was 74-fold more potent than that of tranylcypromine (2-PCPA) and further investigation revealed that compound 8k was active at both recombinant and cell levels by upregulating the expression of H3K4me1, H3 k4me2 and H3k9me2.